The Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging virus that poses a major challenge to clinical management. Highlights:
inhibition by small molecules. We conducted extensive exploration of the pharmacophoric space Highlights:
• MERS-CoV is an emerging virus that is closely related to the bat HKU4-CoV.
• 3CL pro is a potential drug target for coronavirus infection.
• HKU4-CoV 3CL pro is a useful surrogate model for the identification of MERS-CoV 3CL pro enzyme inhibitors.
• dbCICA is a very robust modeling method for hit identification.
• The phenylsulfonamide scaffold represents a potential starting point for MERS coronavirus 3CL pro inhibitors development.
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pro inhibitors, coronavirus, dbCICA, MERS, pharmacophore modeling 2, 3 Since then, over 1900 laboratory-confirmed cases have been reported to the WHO in 27 countries across the world. 4 MERS-CoV is an enveloped virus carrying a genome of positive sense RNA. 5 The virus, which is considered primarily as a zoonotic virus, belongs to the lineage C of Betacoronavirus, thus is closely related to the bat coronaviruses HKU4 and HKU5. [6] [7] [8] Several studies have shown that bats and camels are the most likely animal reservoir of MERS-CoV. [9] [10] [11] Accumulating evidence points to virus transmission from dromedary camels to humans. 12, 13 As the case with many viral diseases, effective therapy against MERS is lacking and supportive care is the only available treatment option. Attempts to develop an effective vaccine against MERS-CoV infection have led to promising results but are still in early stages. [14] [15] [16] The high morbidity and mortality rates of MERS-CoV as well as its potential to cause epidemics highlight the need for novel drug discovery to develop effective and safe anti-MERS-CoV therapeutics.
Several efforts have been undertaken to identify selective potent small molecules with anti-MERS-CoV activity. [17] [18] [19] [20] [21] Promising compounds were identified via screening of FDA-approved drugs and drug-like small molecules using cell-based systems and in vitro screening. [17] [18] [19] [20] [21] [22] [23] [24] Targets homologous to those identified in the severe acute respiratory syndrome coronavirus (SARS-CoV) were investigated in MERS-CoV (reviewed in Hilgenfeld and Peiris 25 ). [26] [27] [28] [29] Among these, MERS-CoV main proteinase, also known as 3-chymotrypsin-like protease (3CL pro ), is considered an important potential target due to its essential role in the viral life cycle. 26, 29 The coronavirus genome encodes an 800-kDa replicase polyprotein, which is processed by the 3CL pro to yield intermediate and mature nonstructural proteins responsible for many aspects of virus replication. 5, 30, 31 The enzyme started to attract interest as a target for anti-MERS-CoV drug development. However, data on the enzyme inhibition are scarce.
The SARS-CoV 3CL pro has been comprehensively explored as a drug target, and many potent enzyme inhibitors have been identified. 1, 25, 32, 33 Elaborated structure-and ligand-based in silico models obtained using the SAR-CoV 3CL pro inhibitors proved fruitless for the identification of MERS-CoV 3CL pro inhibitors (modeling studies conducted by our group, data not published). Interestingly, the 3CL pro enzymes from different CoV strains are known to share significant sequence and 3D structure homology providing a strong structural basis for designing wide-spectrum anti-CoV inhibitors. 34, 35 Sequence alignment studies showed that the active site residues of the HKU4-CoV 3CL pro that participated in inhibitor binding are conserved in the MERS-CoV 3CL pro , which has 81.0% sequence identity 36 to HKU4-CoV 3CL pro ( Figure 1) . Therefore, the bat HKU4-CoV 3CL pro has been investigated as a surrogate model for anti-MERS development. 36 Novel peptidomimetic inhibitors of MERS-CoV 3CL pro have been identified by using the enzyme from HKU4-CoV as a model. 36 In this study, we used the set of peptidomimetic HKU4-CoV estimates were extrapolated based on reported inhibitory percentages at 100μM assuming linear dose-response relationships. The logarithms of measured IC 50 (μM) values were used in QSAR-guided pharmacophore modeling to correlate bioactivity data linearly to free energy change. Chiral centers with unknown configuration were marked as "unknown" so that the inversion these chiral centers is sampled during conformation generation.
These compounds were used to explore the pharmacophoric space of HKU4-CoV 3CL pro through a series of established modeling steps as has been described previously. 38, [42] [43] [44] [45] [46] The modeling workflow is detailed in Sections S1 to S5.
| QSAR modeling
QSAR-guided selection of optimal pharmacophores was conducted to find an optimal combination of pharmacophore models capable of explaining bioactivity variation across the whole set of collected training compounds (1-221, Table S1 ). 36 QSAR modeling was done using the genetic function algorithm (GFA) to generate combinations of descriptors (physicochemical and pharmacophores) (Sections S6 and S7). Subsequently, multiple linear regression (MLR) analyses were used to assess the qualities of selected descriptor combinations, ie, to explain bioactivity variations within collected inhibitors.
This QSAR modeling was performed using a training set of 177 compounds of the total set of HKU4-CoV 3CL pro inhibitors and validated using leave-one-out r 2 (r 2 LOO ) and predictive r 2 (r 2 PRESS ) against a randomly selected testing set of 44 inhibitors as described in Sections S6, S7, and S8. The test set was selected by ranking the total 221 inhibitors according to their IC 50 values, and then every fifth compound was selected for the testing set starting from the high-potency end.
| Docking-based comparative intermolecular contacts analysis
Docking studies were performed using a subset of 27 compounds of the peptidomimetic HKU4-CoV 3CL pro inhibitors with known (absolute) stereochemistries (1-27, Table S1 ). The 3D coordinates of HKU4-CoV 3CL pro were retrieved from the Protein Data Bank (PDB code: 4YOI, 1.8 Å). 36 The protein structure was modified by adding hydrogen atoms and Gasteiger-Marsili charges to the protein atoms using the Discovery Studio (version 2.5.5; Accelrys Inc, San Diego). It was then used in subsequent docking experiments without energy minimization.
Docking was conducted using both LibDock 47 and CDOCKER. 48 LibDock is a site-feature docking algorithm that docks ligands (after removing hydrogen atoms) into an active site guided by binding hotspots. 47 While, CDOCKER is a CHARMm-based simulated annealing/molecular dynamics method that implements simulated annealing to search for the most stable docked ligand poses. 48 These docking engines consider the flexibility of the ligand while treat the receptor as rigid. Details of each docking engine and the corresponding docking settings are described in Sections S9 to S10. The highestranking docked conformers/poses were scored using 7 scoring functions: Jain, LigScore1, LigScore2, PLP1, PLP2, PMF, and PMF04
(Section S11). [49] [50] [51] [52] [53] The docking-scoring cycles using both engines were repeated to cover all possible docking combinations resulting from the presence (or absence) of crystallographically explicit water molecules within the binding site.
Taking into account each scoring function in turn, the highest scoring docked conformer/pose of each inhibitor was chosen to be used in subsequent comparative intermolecular contacts analysis (dbCICA) modeling. 39, 40 This step resulted in 7 docking/scoring combinations of the 27 compounds each of them scored with a corresponding scoring function. The docking and scoring cycle was repeated 2 times to cover all combinations of docking conditions, ie, the presence or absence of explicit water molecules. The resulting 14 docking/scoring sets were used in dbCICA modeling as described previously. 39, 40 Sections S12 to S13 describe details of dbCICA modeling. Successful dbCICA models were used to guide the manual building of pharmacophores (Section S14). Optimal pharmacophores (both structure and ligand based) were validated using the receiver operating characteristic (ROC) curve analysis to assess the ability of each model to correctly classify a group of compounds into actives and inactives (Section S15). 39, 40, 54 Matthews correlation coefficient (MCC) was also undertaken as an additional validation. 55 Additionally, exclusion spheres were added using HIPHOP-REFINE module of Discovery Studio to improve the ROC properties of QSAR-guided pharmacophore (Section S8).
| Virtual screening for new HKU4-CoV 3CL pro inhibitors
The selected pharmacophores were used as 3D search queries to screen the National Cancer Institute (NCI) database 56 for new 3CL pro inhibitors.
Hits captured by the QSAR-guided pharmacophore were filtered by the Lipinski criteria to ensure good pharmacokinetic properties 57 and the SMILES arbitrary target specification (SMARTS) filter (Section S16) to remove reactive ligands (ie, alkyl halides or Michael acceptors). 58 Remaining hits were fitted against the corresponding individual pharmacophores. The fit values were then substituted in the MLR-based QSAR models to predict hits' bioactivities (−log(IC 50 )).
The highest-ranking hits were selected for in vitro testing using a voting system to minimize the influence of QSAR-based predictions on hit prioritization. In this system, each hit fit value and the hit's overall QSAR predictions cast a vote of "one" if the value is within the top 20% of all captured hits, otherwise the vote is "zero."
Similarly, hits captured from all successful dbCICA-derived pharmacophores were pooled together and filtered according to the Lipinski criteria 57 and SMARTS filter. 58 The hits were then docked into HKU4-CoV 3CL pro binding pocket (4YOI) using the same docking/ scoring conditions of each successful dbCICA model. The resulting docked poses were then analyzed for critical contacts (according to successful dbCICA models), and the sums of critical contacts for each hit compound were used for the prediction of their corresponding IC 50 values. The highest-ranking hits were selected for in vitro testing using a similar voting system to that described above: Each docking solution casts a vote of "one" if the predicted value is within the top 10% of all captured hits, otherwise it casts a vote of "zero."
| Protein expression and purification
MERS-CoV 3CL pro was expressed through auto-induction in
Escherichia coli BL21-DE3 cells in the presence of 100 μg/mL of carbenicillin as described previously. 30, 59 Cells were harvested by centrifugation at 5000g for 20 minutes at 4°C, and the pellets were stored at −80°C until further use. MERS-CoV 3CL pro purification was performed using consecutive steps of hydrophobic-interaction chromatography, DEAE anion-exchange chromatography, Mono S cation-exchange chromatography, and size-exclusion chromatography as described previously. 30 HKU4-CoV 3CL pro was produced and purified using a modified protocol from Agnihothram et al. 60 Final protein yield was calculated based on the measurement of total activity units (μM product/min), specific activity (units/mg), and milligrams of protein obtained (BioRad protein assay) after each chromatographic step.
| Inhibition assays
Inhibition assays were conducted as described previously. 36 
where %I max is the percent maximum inhibition of 3CL pro and the error in IC 50 values was determined as the error in the fitted parameter.
Controls were performed, in which the enzyme, the substrate, or both was/were omitted. Fluorescence attenuation controls were carried by adding the inhibitors to the cleaved substrate in a reaction mixture identical to that used in the inhibition assays. The fit values obtained by mapping the 68 representative pharmacophores against the HKU4-CoV 3CL pro inhibitors were enrolled together with a selection of 2D descriptors as independent variables in QSAR analysis.
Genetic function algorithm combined with MLR analyses was used to select different combinations of pharmacophores and 2D molecular descriptors that are capable of explaining bioactivity variation among collected inhibitors.
However, all attempts to achieve statistically successful QSAR models failed, prompting the use of ligand efficiency [LE = −log(IC 50 )/ heavy atom count] as an alternative response variable instead of −log(IC 50 ). [61] [62] [63] [64] The best QSAR models are summarized in Equations 3 and 4. Figure 2A , B show the corresponding scatter plots of experimental versus estimated bioactivities for training and testing inhibitors. 
where n is the number of training compounds used to generate this pharmacophores (see Table S3 ). Figure 3 shows the 3 pharmacophores and how they fit the most potent training compound (Table 1) . Furthermore, MCC of the Table S6 . HBA, hydrogen bond acceptor; HBD, hydrogen bond donor 3 pharmacophores reflects the very weak classification abilities of Hypo(L-T5-2) ( Table 1 (Table 1) . Merging pharmacophores that share common features has been reported to improve the performance of pharmacophores in capturing active molecules. 66 Additionally, Hypo(K-T5-3/N-T1-1) was further modified by adding exclusion spheres (Section S8 and Table S6 ) to further enhance its ROC profile (Table 1) . Exclusion volumes resemble inaccessible regions within the binding site. Figure 3D shows the sterically refined version of 
| Structure-based approach: dbCICA modeling
Structure-based pharmacophore models for HKU4-CoV 3CL pro were obtained by using dbCICA. In this approach, a subset of inhibitors (1-27, Table S1 ) were docked into the HKU4-CoV 3CL pro binding pocket using LibDock, 47 and CDOCKER 48 (Section 2.2). The highestranking conformers/poses based on each scoring function were aligned together to construct a corresponding dbCICA model. Genetic algorithm was then used to search for the best combination of ligandreceptor intermolecular contacts capable of explaining bioactivity variation across the training compounds. Table 2 shows the contacts distance thresholds, number of positive and negative contacts, and statistical criteria of the best dbCICA models. Table 3 shows the critical binding site contact atoms proposed by optimal dbCICA models. The highest-ranking dbCICA models exhibited excellent statistical criteria and were anticipated to act as good templates for building corresponding pharmacophore models (Table 2 ). Abbreviation: dbCICA, docking-based comparative intermolecular contacts analysis. a As in Table 2 .
b Bioactivity-proportional ligand/binding site contacts. Finally, all contacts points of negative correlation with bioactivity were assumed to represent areas of steric clashes with the bound ligand. Therefore, such contacts were used to define exclusion volumes within the vicinity of the binding pocket, as shown in Figure 4E .
The same strategy was used to translate all other optimal dbCICA models in Tables 2 and 3 into their corresponding pharmacophore models ( Figure 5 ). The X, Y, and Z coordinates of the resulting pharmacophores are shown in Table S7 . Subsequent validation using ROC analysis (Table 4) .illustrated the excellent classification powers of these pharmacophores in distinguishing actives from decoys.
Matthews correlation coefficient values indicate that the structurebased dbCICA models are superior in their classification ability to the QSAR-guided pharmacophores.
| In silico screening
The QSAR-guided, sterically refined, merged pharmacophore Hypo(K- On the other hand, filtered dbCICA-derived hits were docked into HKU4-3CL pro protein using the same docking conditions of each . The hits were ranked and prioritized using the voting system described in Section 2.4, and the top 39 compounds were acquired for in vitro testing. Thus, the total of 78 compounds from the NCI Open Chemicals Repository were acquired for testing.
| In vitro validation
A total of 78 NCI ( Figure S1 ), 39 QSAR-guided derived hits and 39 dbCICA derived hits, compounds were acquired and screened in vitro to determine their inhibitory activity against HKU4-CoV-3CL pro and MERS-CoV-3CL pro at 40μM hit concentration. The 3CL pro enzyme assay used in this study was carefully designed to avoid misleading false positives and to prevent wasted follow-up on promiscuous compounds (by adding albumin, DTT, and triton-100 to the reaction mixture). Tables S8 and S9 show the %inhibition against 3CL pro of the hits captured by the QSAR-guided and the dbCICA derived pharmacophores, respectively.
Only a single compound (NCI code 134140) of the 39 tested hits, captured by the QSAR-guided pharmacophores, showed inhibitory activity ≥50% against both HKU4-CoV 3CL pro and MERS-CoV 3CL pro .
However, this compound has a molecular fragment known to cause pan assay interference (PAINS-like; Baell
67
) and therefore was not considered as a hit in further characterizations. Three compounds of the same ligand-based hits (NCI codes: 12156, 22906, and 28562; Table   S8 ) showed unexpectedly high negative values of their activity against MERS-CoV 3CL pro (−633.2%, −203.4%, and −662.6% at 40μM; Table   S8 ). Several controls were performed in which either the substrate or the enzyme or both were omitted from the assay (data not shown).
None of these hits showed evidence of fluorescence interference. It might be possible that these compounds act as activators of the enzyme. However, further evidence is still needed to support this hypothesis. It was previously observed that designed reversible peptidomimetic inhibitors acted as activators at a low compound concentration as a result of induced dimerization. 30 Therefore, these 3 hits will not be discussed in the current publication. Figure 6 ). However, the compound 222 failed to show significant inhibitory activity against HKU4-CoV 3CL
pro .
The purity of 222 was confirmed using nuclear magnetic resonance and mass spectroscopy ( Figure S2 ). Another compound, 223, was found to exhibit a bit lower activity against the MERS-CoV enzyme (28% inhibition at 40μM). The purity of 223 was confirmed using nuclear magnetic resonance and mass spectroscopy ( Figure S3 ).
Compounds 222 and 223 (NCI code 128947) share a common phenylsulfonamide fragment, which is amenable to chemical modifications. Both compounds were captured by Hypo(SB-3) and Hypo(SB-5) pharmacophores (Table 4 ). Figure 7 shows how 222 hit maps the dbCICA pharmacophore models. indicates the influence of the inner filter effect ( Figure S4 ). 68, 69 Inner filter effect is one of the major challenges usually encountered in FRET-based enzyme assays. 69 The low hit rate observed in this study can be justified by the limited availability of many of the top-ranked hits in the NCI Open Clearly, the quality of the training set is a pivotal factor in determining the predictive validity of the obtained pharmacophores.
It is also worth noting that the active site-directed design of nonpeptidomimetic small molecule inhibitors of proteases is often challenging because of the unique chemistry of the peptide-bond cleavage transition state and because some proteases cleave their substrates through an induced fit mechanism. Successful dbCICA models can then be translated into binding models (pharmacophores) to be used as in silico screening tools of virtual databases.
We have applied these robust computational methods to model HKU4-CoV 3CL pro inhibitors as a tool to identify inhibitors of MERS-CoV 3CL
pro . These models assisted the identification of 2 hit compounds with moderate apparent activity against MERS-CoV 3CL pro . The identified inhibitors share a novel nonpeptidomimetic scaffold that is amenable to medicinal chemistry optimization efforts.
Despite the fair inhibitory activity of this scaffold, it represents a potential starting point in the discovery of novel MERS-CoV antivirals.
There are several successful examples in the history of drug discovery in which the starting hits showed low-to-moderate enzyme inhibition.
For example, the millimolar inhibitor Neu5Ac was the starting point in the development of zanamivir, the first influenza neuraminidase inhibitor introduced to the market. 71 Most importantly, the established ligand-based and structurebased pharmacophore models aid as tools for advancing our understanding of small molecule recognition of the coronavirus 3CL 
